History
Leveraging commercialization expertise, GBIOLOGICS accelerates market entry through optimized development
Selected as a Baby Unicorn Company
Publication of GB910 in Molecular Therapy
GB910 U.S. Patent Registration
GB930 Korean Patent Registration
Winner of the Seoul–BMS Innovation Square Challenge
Completion of sGal‑9 GMP production
GB910 patent registrations (Japan and Australia)
Co-development agreement with Kolon Pharma for GB930
GLP‑TOX studies
Efficacy studies in SLE, RA, and Cancer
Co-development agreement with PLATBio for GB920
Series A funding secured: KRW 8.9 billion
GB910/RA indication patent registration
Establishment of sGal‑9 manufacturing process
Venture company certification (No. 20190402684)
Establishment of Coportate R&D center
Transfer of ownership for sGal‑9 material patents (U.S., Japan)
Establishment of GBIOLOGICS, Inc.
Leadership
Experts with decades of strategic R&D and commercialization experience in the global pharmaceutical industry come together,
creating synergy through their collective expertise
David Song
A leader with extensive biopharmaceutical expertise
and strategic vision for global market success
Professional background
Awards & Honors
Yeong Ho Song
CSO
30+ years of experience in Biopharma R&D and Business Development, Including IPOs and Capital Strategy
Misuk Kang, PhD
CTO
15 + years of experience in Research and Clinical Development of Biologics
Si Hyung Cho
CFO
20+ years of Leadership in Corporate Finance, M&A, and Strategic Capital Management
